Can Stem Cells Help With Drug-Resistant Focal Epilepsy?

What This Article Covers

For the roughly one-third of epilepsy patients whose seizures don't respond to medication, a new investigational approach is generating real excitement in neurology: transplanting lab-grown, stem-cell-derived interneurons directly into the brain to restore the inhibitory signaling that keeps seizures in check. This article examines the actual clinical evidence behind this therapy — led by Neurona Therapeutics' NRTX-1001 program — including trial design, reported seizure-reduction outcomes, safety data, and regulatory status, while being clear about what remains unproven.

Overview

Drug-resistant epilepsy, most commonly mesial temporal lobe epilepsy (MTLE), affects people whose seizures continue despite trying two or more anti-seizure medications. Historically, the main option for these patients has been resective brain surgery — removing the seizure-generating tissue, typically in the hippocampus — which can be effective but carries risks to memory and other cognitive functions, and isn't suitable or desired by every candidate. Over the past several years, researchers have been testing a fundamentally different strategy: instead of removing tissue, transplant new inhibitory neurons into the affected region to rebalance the brain's excitatory-inhibitory circuitry. The furthest-along program, NRTX-1001, is being developed by Neurona Therapeutics and is currently in a multicenter Phase 1/2 clinical trial (ClinicalTrials.gov identifier NCT05135091) at academic epilepsy centers including the University of Chicago and the University of Arkansas for Medical Sciences.

How It's Thought to Work

NRTX-1001 consists of GABAergic interneurons — inhibitory nerve cells — derived from human pluripotent stem cells in the laboratory. In drug-resistant MTLE, an imbalance often develops between excitatory and inhibitory signaling in the hippocampus, contributing to recurrent seizures. Using a stereotactic surgical robot, surgeons inject a suspension of these interneurons directly into the hippocampus in a single procedure. The cells are designed to engraft, mature, and release GABA — the brain's primary inhibitory neurotransmitter — locally dampening the hyperexcitable circuits that trigger seizures, rather than silencing or removing brain tissue altogether. Preclinical work in animal models, reviewed in a 2025 Epilepsy Currents article by Wesleyan University researcher Janice Naegele, showed that transplanted interneurons suppressed seizures within about six weeks in rodents; human-derived cells appear to need longer, on the order of three to five months, to functionally integrate.

What the Evidence Shows

This is where there's genuine reason for cautious optimism. An abstract presented at the American Epilepsy Society's 2024 annual meeting, based on ten treated subjects as of May 2024, reported a median 75% reduction in monthly seizures from baseline in the low-dose cohort, with 80% of subjects experiencing at least a 50% reduction and 60% becoming free of their most disabling seizure type; subjects with longer follow-up showed a 98% median seizure reduction in months seven through twelve. Longer-term data presented at the AES 2025 annual meeting, drawn from 26 patients treated across the expanding trial, showed an 89% median seizure reduction at the primary endpoint in the low-dose unilateral MTLE cohort (sustained near 92% beyond 13 months in patients with two-plus years of follow-up), a 78% median reduction in an interim high-dose cohort, and reductions of 88-93% in smaller cohorts with bilateral or non-lesional epilepsy. No serious adverse events were attributed to NRTX-1001 itself; reported adverse events were mild-to-moderate and related either to the surgical procedure or to the temporary immunosuppression regimen used to protect the graft, and most resolved per protocol. On the strength of this early data, the FDA granted NRTX-1001 Regenerative Medicine Advanced Therapy (RMAT) designation in June 2024, and the European Medicines Agency granted PRIME designation in October 2025 — both signals that regulators see promise, not confirmation of effectiveness. A registrational Phase 3 trial (EPIC) is planned to begin dosing in the first half of 2026. It's essential to note this remains an open-label, non-randomized early-phase trial without a completed placebo-controlled comparison, involving only dozens of patients; larger, blinded studies are needed before conclusions about true efficacy can be drawn.

Who Might Be a Candidate

Based on current trial eligibility criteria, people being evaluated for this type of investigational therapy generally:

• Have a confirmed diagnosis of drug-resistant unilateral or bilateral mesial temporal lobe epilepsy
• Have tried and not adequately responded to at least two appropriate anti-seizure medications
• Have ongoing, frequent seizures despite stable medication use
• Are being evaluated through an academic epilepsy center participating in a registered clinical trial
• Are not appropriate candidates for, or wish to avoid, standard resective epilepsy surgery

Bottom Line

Stem-cell-derived interneuron therapy for drug-resistant focal epilepsy represents one of the more scientifically compelling emerging cell-therapy programs in neurology, with early trial data showing seizure reductions in the 75-95% range for many treated patients and a favorable safety profile so far. That said, this treatment is entirely investigational, available only within registered clinical trials, and has not been evaluated in a completed randomized, placebo-controlled study — a critical next step given how variable seizure frequency can be on its own. It is not FDA-approved, and no legitimate clinic can currently offer it outside a formal trial setting. Patients interested in this approach should discuss trial eligibility with an academic epilepsy center and treat any commercial "stem cell for epilepsy" offer outside a registered trial with serious skepticism.